Back

Prolonged ventricular activation time as a novel biomarker identifying burn-out phase of hypertrophic cardiomyopathy

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Hypertrophic cardiomyopathy: risk prediction and outcomes Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Konstantinos Fragkiadakis

University Hospital of Heraklion, Heraklion (Greece)

6 More presentations in this session

Presentation thumbnail
CMR phenotypes and clinical outcomes in NYHA class I versus II-IV hypertrophic cardiomyopathy: identifying high-risk asymptomatic patients
Doctor D. Labib (Calgary, CA)
Abstract Slides Video
Presentation thumbnail
High-intensity exercise-related sudden cardiac death in hypertrophy cardiomyopathy
Doctor H. Lee (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
One-year outcomes of patients with hypertrophic cardiomyopathy according to levels of inflammatory biomarkers
Doctor M. Golino (Jacksonville, US)
Abstract Slides Video
Presentation thumbnail
The relationship between serum lumican levels and myocardial fibrosis in patients with hypertrophic cardiomyopathy
Doctor E. Hancioglu (Hatay, TR)
Abstract Slides Video
Presentation thumbnail
Invasive quantitative assessment of coronary microvascular dysfunction in patients with hypertrophic cardiomyopathy
Doctor M. Marques Antunes (Lisboa, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy: risk prediction and outcomes

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Low left atrium reservoir strain predicts complex ventricular arrhythmias and burnout phase in hypertrophic cardiomyopathy.
thumbnail
Congress Presentation
The prognostic role of novel echocardiographic global functional indexes in hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Longitudinal changes of left ventricular geometry and relationship with cardiac outcomes in patients with hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources